<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02645565</url>
  </required_header>
  <id_info>
    <org_study_id>JIP/IEC/SC/2013/5/435</org_study_id>
    <nct_id>NCT02645565</nct_id>
  </id_info>
  <brief_title>Comparison of Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Lupus Nephritis</brief_title>
  <official_title>Comparison of Intravenous Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Proliferative Lupus Nephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jawaharlal Institute of Postgraduate Medical Education &amp; Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jawaharlal Institute of Postgraduate Medical Education &amp; Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to find out whether low dose or high dose cyclophosphamide&#xD;
      therapy is effective in the treatment of proliferative lupus nephritis.It will also compare&#xD;
      the side effects and risks of infection in low dose and high dose cyclophosphamide group.&#xD;
      Half of the participants will receive a low dose cyclophosphamide for 3 months and half will&#xD;
      receive high dose cyclophosphamide therapy monthly for 6 months followed by azathioprine 2&#xD;
      mg/kg.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted at the Department of Clinical Immunology, Jawaharlal Institute of&#xD;
      Postgraduate Medical Education &amp; Research (JIPMER). Once the patients are diagnosed to have&#xD;
      systemic lupus erythematosus (SLE) lupus nephritis and they satisfy the inclusion criteria ,&#xD;
      they will be informed about the nature and severity of the disease and about the expected&#xD;
      treatment options and the duration of treatment. After providing written informed consent,&#xD;
      eligible patients will be stratified into two groups. Block randomization will be done to&#xD;
      generate random allocation sequence.They will receive either a low dose or high dose&#xD;
      Cyclophosphamide as per the protocol mentioned below:&#xD;
&#xD;
      Group I : Low dose arm : Intravenous cyclophosphamide fixed pulse 500 mg each 2 weekly total&#xD;
      6 doses followed by azathioprine 2 mg/kg.&#xD;
&#xD;
      Group II : High Dose arm : Intravenous cyclophosphamide therapy 750 mg/m2 will be given every&#xD;
      4 weekly for total 6 doses followed by azathioprine 2 mg/kg.&#xD;
&#xD;
      Intravenous methylprednisolone pulses 1 gm each will be given for 3 days in both the&#xD;
      treatment arms followed by prednisolone 1 mg/kg for 4 weeks and then tapering 5 mg every 2&#xD;
      weeks.&#xD;
&#xD;
      Additional drugs as per indication like hydroxychloroquine, antihypertensives and&#xD;
      cotrimoxazole prophylaxis shall also be given unless contraindicated.&#xD;
&#xD;
      There will be monitoring of treatment efficacy and side effects in each treatment arm&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Primary Renal Response</measure>
    <time_frame>12 months</time_frame>
    <description>Renal response as by the EULAR guidelines will be evaluated at 12 months for low dose group and high dose cyclophosphamide group. Inactive urinary sediments defined by ≤5 red blood cells (RBC)/hpf, ≤5 white blood cells (WBC)/hpf and no cellular casts as per the American college of rheumatology (ACR) definition.&#xD;
Complete Response (CR) with urine protein creatinine ratio(UPCR) &lt;0.5 gm and Normal (GFR &gt; 90 ml/min) or stable (&lt;10% deterioration from baseline if GFR was previously abnormal) renal function and inactive urinary sediments.&#xD;
Partial Response(PR) , defined as ≥50% reduction in proteinuria to subnephrotic levels , normal (GFR &gt; 90 ml/min) or stable (&lt;10% deterioration from baseline if GFR was previously abnormal) renal function and inactive urinary sediments.&#xD;
No Response : Patients will be classified as non responders if criteria for CR or PR are not met and or if they experience severe flare.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with Renal and Non renal disease flares</measure>
    <time_frame>12 months</time_frame>
    <description>Nephritic flares consist of a reproducible increase in serum creatinine (SCr) concentration of 30% or more (or a reduction in glomerular filtration rate [GFR] by 10% or more) and active urine sediment with an increase in glomerular hematuria by 10 or more red blood cells per high power field, irrespective of changes in UPCR. Proteinuric flares consist of a reproducible doubling of urine protein to creatinine ratio (UPCR) to more than 1.0 after complete renal response or a reproducible doubling of UPCR to more than 2.0 after partial response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of adverse events</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>Low dose Cyclophosphamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous Cyclophosphamide therapy 500 mg intravenous 2 weekly for 3 months followed by azathioprine 2 mg/kg. Injectable methylprednisolone 1 gm pulse will be given for 3 days before starting the first pulse of cyclophosphamide followed by oral prednisolone 1 mg/kg for 4 weeks and then tapering 5 mg every 2 weeks till 7.5 mg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Cyclophosphamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous Cyclophosphamide therapy 750mg/m2 intravenous 4 weekly for 6 months followed by azathioprine 2mg/kg. Injectable methylprednisolone 1 gm pulse will be given for 3 days before starting the first pulse of cyclophosphamide followed by oral prednisolone 1 mg/kg for 4 weeks and then tapering 5 mg every 2 weeks till 7.5 mg/day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide is an alkylating agent used for the treatment of lupus nephritis.</description>
    <arm_group_label>High Dose Cyclophosphamide</arm_group_label>
    <arm_group_label>Low dose Cyclophosphamide</arm_group_label>
    <other_name>Endoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azathioprine</intervention_name>
    <description>azathioprine will be given at 2 mg/kg.</description>
    <arm_group_label>High Dose Cyclophosphamide</arm_group_label>
    <arm_group_label>Low dose Cyclophosphamide</arm_group_label>
    <other_name>Imuran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Each treatment arm shall receive 1 gm methylprednisolone pulse for 3 days followed by prednisolone 1 mg/kg for 4 weeks and tapered 5 mg every 2 weekly ,to maintain 7.5 mg dose daily</description>
    <arm_group_label>High Dose Cyclophosphamide</arm_group_label>
    <arm_group_label>Low dose Cyclophosphamide</arm_group_label>
    <other_name>prednisolone,steroid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A diagnosis of SLE according to the American College of Rheumatology (ACR) criteria&#xD;
&#xD;
          2. Age &gt;16 years&#xD;
&#xD;
          3. Proteinuria ≥500 mg in 24 hours/ urine routine microscopy showing active cellular&#xD;
             casts/sediments.&#xD;
&#xD;
          4. Biopsy-proven proliferative lupus glomerulonephritis of class III, IV according to the&#xD;
             International Society of Nephrology/Renal Pathology Society (ISN/RPS) criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients ever treated previously with intravenous or oral cyclophosphamide or received&#xD;
             steroids &gt;15mg/day in the last 3 months.&#xD;
&#xD;
          2. Patients with renal thrombotic microangiopathy, preexisting chronic renal failure,&#xD;
             pregnancy, previous malignancy (except skin and cervical intraepithelial neoplasia),&#xD;
             diabetes mellitus or coronary heart disease.&#xD;
&#xD;
          3. Patients with previously documented severe toxicity to immunosuppressive drugs.&#xD;
&#xD;
          4. Patients with acute/chronic infections.&#xD;
&#xD;
          5. Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Vir Singh Negi, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jawaharlal Institute of Postgraduate Medical Education &amp; Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Sonal Mehra, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jawaharlal Institute of Postgraduate Medical Education &amp; Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Immunology , Jawaharlal Institute of Post graduate Medical Educationa and Research</name>
      <address>
        <city>Pondicherry</city>
        <zip>605006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>December 30, 2015</study_first_submitted>
  <study_first_submitted_qc>December 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2016</study_first_posted>
  <last_update_submitted>March 2, 2017</last_update_submitted>
  <last_update_submitted_qc>March 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jawaharlal Institute of Postgraduate Medical Education &amp; Research</investigator_affiliation>
    <investigator_full_name>Dr. Vir Singh Negi</investigator_full_name>
    <investigator_title>Head of the department and Proffessor of Clinical Immunology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 12, 2021</submitted>
    <returned>March 5, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

